Dg Lubricant Eye Drops

Polyethylene Glycol 400, Propylene Glycol


Dolgencorp Llc
Human Otc Drug
NDC 55910-364
Dg Lubricant Eye Drops also known as Polyethylene Glycol 400, Propylene Glycol is a human otc drug labeled by 'Dolgencorp Llc'. National Drug Code (NDC) number for Dg Lubricant Eye Drops is 55910-364. This drug is available in dosage form of Solution. The names of the active, medicinal ingredients in Dg Lubricant Eye Drops drug includes Polyethylene Glycol 400 - .4 g/100mL Propylene Glycol - .3 g/100mL . The currest status of Dg Lubricant Eye Drops drug is Active.

Drug Information:

Drug NDC: 55910-364
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Dg Lubricant Eye Drops
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Polyethylene Glycol 400, Propylene Glycol
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Dolgencorp Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:POLYETHYLENE GLYCOL 400 - .4 g/100mL
PROPYLENE GLYCOL - .3 g/100mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:OPHTHALMIC
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 27 Jan, 2020
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 21 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part349
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Dolgencorp LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:477589
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:B697894SGQ
6DC9Q167V3
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
55910-364-011 BOTTLE, DROPPER in 1 CARTON (55910-364-01) / 15 mL in 1 BOTTLE, DROPPER27 Jan, 2020N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Active ingredients polyethylene glycol .....lubricant propylene glycol.....lubricant

Product Elements:

Dg lubricant eye drops polyethylene glycol 400, propylene glycol calcium chloride hypromellose, unspecified sodium borate boric acid potassium chloride benzalkonium chloride zinc chloride propylene glycol propylene glycol magnesium chloride water sodium chloride polyethylene glycol 400 polyethylene glycol 400

Indications and Usage:

Uses for the temporary relief of burning and irritation due to dryness of the eye

Warnings:

Warnngs for external use only do not use if this product changes color or becomes cloudy if you are sensitive to any ingredient in this product when using this product do not touch the tip of container to any surface to avoid contamination replace cap after each use stop use and ask a doctor if you feel eye pain changes in vision occur redness or irritation of the eye(s) gets worse or lasts more than 72 hours keep out of reach of children if swallowed, get medical help or contact a poison control center right away

Do Not Use:

Warnngs for external use only do not use if this product changes color or becomes cloudy if you are sensitive to any ingredient in this product when using this product do not touch the tip of container to any surface to avoid contamination replace cap after each use stop use and ask a doctor if you feel eye pain changes in vision occur redness or irritation of the eye(s) gets worse or lasts more than 72 hours keep out of reach of children if swallowed, get medical help or contact a poison control center right away

When Using:

When using this product do not touch the tip of container to any surface to avoid contamination replace cap after each use

Dosage and Administration:

Directions instill 1 or 2 drops in the affected eye(s) as needed children under 6 years of age: ask a doctor

Stop Use:

Stop use and ask a doctor if you feel eye pain changes in vision occur redness or irritation of the eye(s) gets worse or lasts more than 72 hours

Package Label Principal Display Panel:

Carton


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.